XML 11 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2021
Dec. 31, 2020
ASSETS    
Cash and cash equivalents $ 12,935 $ 16,512
Marketable securities 93,155 18,061
Prepaid and other current assets 1,990 758
Total current assets 108,080 35,331
Property and equipment, net 84 57
Other assets 450 614
Total assets 108,614 36,002
Liabilities    
Accounts payable 1,242 1,020
Accrued liabilities 2,614 2,486
Total current liabilities 3,856 3,506
Other long-term liabilities 79 254
Total liabilities 3,935 3,760
Commitments and Contingencies
Stockholders' Equity    
Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.001 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at June 30, 2021 and December 31, 2020, respectively 0 0
Common stock, $0.001 par value, authorized 500,000,000 shares; issued 59,528,538 and 19,389,413 shares at June 30, 2021 and December 31, 2020, respectively; and outstanding, 59,517,458 and 19,378,333 shares at June 30, 2021 and December 31, 2020, respectively 60 19
Additional paid-in capital 544,893 458,748
Treasury stock, at cost; 11,080 shares at June 30, 2021 and December 31, 2020 (708) (708)
Accumulated deficit (439,295) (425,550)
Accumulated other comprehensive loss (17) (13)
Total Caladrius Biosciences, Inc. stockholders' equity 104,933 32,496
Noncontrolling interests (254) (254)
Total stockholders' equity 104,679 32,242
Liabilities and Equity, Total $ 108,614 $ 36,002